Trial Profile

A Phase 1, Multicentre, Open-label, Nonrandomised, First-in-human Study of OVM-200 As a Therapeutic Vaccine in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Ovarian Cancer, and Prostate Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Aug 2026 According to a Dx & Vx media release, company has successfully completed Phase 1 clinical trials this year.
30 Aug 2026 Status changed from recruiting to completed, according to a Dx & Vx media release.
06 Jul 2026 According to a Dx & Vx media release, data from this study was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in May.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com